Funds › Aisling Capital Management LP
Aisling Capital Management LP
13F for Q3 2026, filed Nov 12, 2026. 14 positions worth $299.3M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Aisling Capital Management LP in the latest 13F quarter?
Using 13F.ai, how has Aisling Capital Management LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Aisling Capital Management LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | BBIO BridgeBio Pharma, Inc. | 3.09M | $203.3M | 67.9% | -32.7% | 13F ↗ |
| 2 | SNDX Syndax Pharmaceuticals, Inc. | 1.32M | $24.8M | 8.3% | Unchanged | 13F ↗ |
| 3 | CMPS COMPASS Pathways Plc · ADR | 1.73M | $21.6M | 7.2% | +20.9% | 13F ↗ |
| 4 | GLUE Monte Rosa Therapeutics, Inc. | 1.56M | $18.6M | 6.2% | Unchanged | 13F ↗ |
| 5 | BCAX Bicara Therapeutics Inc. | 548,919 | $10.2M | 3.4% | -3.5% | 13F ↗ |
| 6 | URGN UroGen Pharma Ltd. | 108,000 | $4.4M | 1.5% | Unchanged | 13F ↗ |
| 7 | BBOT BridgeBio Oncology Therapeutics, Inc. | 1.02M | $4.1M | 1.4% | Unchanged | 13F ↗ |
| 8 | EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 325,000 | $3.0M | 1.0% | Unchanged | 13F ↗ |
| 9 | BMEA Biomea Fusion, Inc. | 2.05M | $2.7M | 0.9% | Unchanged | 13F ↗ |
| 10 | ACRS Aclaris Therapeutics, Inc. | 434,455 | $2.3M | 0.8% | Unchanged | 13F ↗ |
| 11 | SRRK Scholar Rock Holding Corporation | 42,031 | $2.0M | 0.7% | -45.4% | 13F ↗ |
| 12 | VTVT vTv Therapeutics Inc. | 58,775 | $1.8M | 0.6% | +17.5% | 13F ↗ |
| 13 | MRKR Marker Therapeutics, Inc. | 325,370 | $348.1K | 0.1% | Unchanged | 13F ↗ |
| 14 | OKUR OnKure Therapeutics, Inc. | 88,607 | $241.5K | 0.1% | Unchanged | 13F ↗ |
Changes since Q2 2026
0 new, 2 added to, 3 trimmed, 0 exited, 9 unchanged. By estimated dollars.
New positions (0)
None this quarter.
Added to (2)
Trimmed (3)
Exited (0)
None this quarter.
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 12, 2026 | 13F-HR | 14 | $299.3M | Current | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | 13F-HR | 14 | $471.6M | Current | SEC ↗ |
| Q1 2026 | May 5, 2026 | 13F-HR | 13 | $476.3M | Current | SEC ↗ |
| Q4 2025 | Feb 10, 2026 | 13F-HR | 13 | $478.9M | Current | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | 13F-HR | 14 | $456.4M | Current | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | 13F-HR | 13 | $359.7M | Current | SEC ↗ |
| Q1 2025 | May 13, 2025 | 13F-HR | 13 | $288.5M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer